I'm joined this week by Brian Finrow, CEO of Lumen Bioscience, who thinks we would be better off if we grew more drugs in algae, and fewer in Chinese Hamster Ovary cells. We talk about why "monoclonal antibodies" are particularly safe and effective as drugs—but incredibly expensive to manufacture—and whether the fundamental problem of the biotech industry is that everyone just has too much money.Full transcript at https://developmentandresearch.bio/episode/brian-finrow/
--------
1:23:10
Meri Beckwith: How (not) to waste a billion dollars (on your clinical trial)
I'm joined this week by Meri Beckwith, who founded Lindus Health after being a clinical trial patient—because he was astounded at how badly clinical drug trials were being run by the world's leading companies.We talk about why clinical trials companies are twenty years behind in adopting new technologies, how a flooded supply closet can cause a billion-dollar clinical trial to fail, and his speculation about the incentives that—so far—have stopped the world from getting better.
--------
56:26
Development And Research Trailer
Development & Research is a video series about doing things differently in the world of clinical trials. Development and Research is produced by Samuel Cottrell (hath.blog)Thank you to Michael Curzi at Hallsong Media (hallsong.com) for producing the trailer.
The clinical trials process is broken. It is unbelievably expensive and slow: it takes more than ten years and a billion dollars to get a typical drug approved. Join Ross Rheingans-Yoo on Development & Research—a new video series on fixing drug development, with new episodes on Tuesdays.
Colombia